

Australian Clinical Labs Limited

ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia **clinicallabs.com.au**

Tuesday, 4 July 2023

Chair to take temporary leave

Australian Clinical Labs Limited (ASX:ACL) (**ACL** or **Company**) wishes to advise the market that its Chair, Mr Michael Alscher, is taking temporary leave to recover from a surgical procedure.

Mr Daren McKennay has been appointed by the Board as Michael's alternate director. Daren is a partner at Crescent Capital Partners and has held Chair, CEO and director roles in healthcare including primary care, diagnostic imaging, private hospitals, pathology, clinical research and medical devices in both public and private company environments over 32 years.

The Board has determined that Daren will be Acting Chair given his previous experience with the Company and his deep experience in pathology and the healthcare sector.

– ENDS –

This announcement was authorised for release to the ASX by the ACL Board. For further information regarding this announcement, please contact:

Investors Eleanor Padman Company Secretary Email: <u>epadman@padmanadvisory.com.au</u> Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.